Rep. Robert Bresnahan, Jr. Sells Off Shares of Waters Co. (NYSE:WAT)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Waters Co. NYSE: WAT. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Waters stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Occidental Petroleum NYSE: OXY on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 4/8/2025.
• Sold $1,001 - $15,000 in shares of QUALCOMM NASDAQ: QCOM on 4/8/2025.

Waters Stock Down 2.0 %

Shares of NYSE WAT traded down $7.15 during trading on Friday, hitting $343.73. 355,902 shares of the company traded hands, compared to its average volume of 476,728. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.65 and a current ratio of 0.94. The business's fifty day moving average is $349.55 and its 200 day moving average is $369.86. The firm has a market capitalization of $20.45 billion, a price-to-earnings ratio of 32.09, a P/E/G ratio of 3.79 and a beta of 1.14. Waters Co. has a fifty-two week low of $279.24 and a fifty-two week high of $423.56.

Waters (NYSE:WAT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical instruments supplier reported $2.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.03. The business had revenue of $661.71 million for the quarter, compared to analyst estimates of $655.50 million. Waters had a return on equity of 46.31% and a net margin of 21.56%. The company's quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.21 earnings per share. Equities research analysts predict that Waters Co. will post 12.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wealthfront Advisers LLC boosted its position in Waters by 106,144.4% during the fourth quarter. Wealthfront Advisers LLC now owns 3,087,461 shares of the medical instruments supplier's stock worth $1,145,386,000 after purchasing an additional 3,084,555 shares during the period. Norges Bank bought a new position in Waters in the 4th quarter worth approximately $284,415,000. GAMMA Investing LLC grew its stake in Waters by 50,228.3% in the 1st quarter. GAMMA Investing LLC now owns 662,320 shares of the medical instruments supplier's stock valued at $244,111,000 after buying an additional 661,004 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd raised its holdings in Waters by 676.8% during the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 705,733 shares of the medical instruments supplier's stock valued at $260,112,000 after acquiring an additional 614,877 shares during the period. Finally, Millennium Management LLC lifted its position in shares of Waters by 3,349.7% during the fourth quarter. Millennium Management LLC now owns 304,404 shares of the medical instruments supplier's stock worth $112,928,000 after acquiring an additional 295,580 shares in the last quarter. Institutional investors own 94.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on WAT. Robert W. Baird raised their price target on shares of Waters from $355.00 to $374.00 and gave the company an "outperform" rating in a research report on Wednesday. Scotiabank raised Waters from a "sector perform" rating to a "sector outperform" rating and lifted their target price for the company from $430.00 to $450.00 in a research report on Thursday, February 13th. Sanford C. Bernstein set a $400.00 price target on Waters and gave the stock an "outperform" rating in a report on Wednesday, April 16th. JPMorgan Chase & Co. upped their target price on shares of Waters from $380.00 to $390.00 and gave the stock a "neutral" rating in a research note on Thursday, March 6th. Finally, StockNews.com lowered shares of Waters from a "buy" rating to a "hold" rating in a research report on Tuesday, February 25th. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $390.19.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.